Nurix Therapeutics Inc (NASDAQ: NRIX) kicked off on Friday, up 7.20% from the previous trading day, before settling in for the closing price of $8.33. Over the past 52 weeks, NRIX has traded in a range of $8.18-$29.56.
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -38.86%. While this was happening, its average annual earnings per share was recorded -0.41%. With a float of $74.92 million, this company’s outstanding shares have now reached $76.43 million.
Nurix Therapeutics Inc (NRIX) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Nurix Therapeutics Inc is 1.99%, while institutional ownership is 115.91%. The most recent insider transaction that took place on Aug 01 ’25, was worth 59,598. In this transaction Chief Financial Officer of this company sold 5,402 shares at a rate of $11.03, taking the stock ownership to the 35,512 shares. Before that another transaction happened on Aug 01 ’25, when Company’s Officer proposed sale 5,402 for $11.26, making the entire transaction worth $60,827.
Nurix Therapeutics Inc (NRIX) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 8/31/2024, the organization reported -0.67 earnings per share (EPS), higher than consensus estimate (set at -0.68) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.89 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -0.41% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -5.78% during the next five years compared to -38.86% drop over the previous five years of trading.
Nurix Therapeutics Inc (NASDAQ: NRIX) Trading Performance Indicators
Take a look at Nurix Therapeutics Inc’s (NRIX) current performance indicators. Last quarter, stock had a quick ratio of 6.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.72.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.61, a number that is poised to hit -0.82 in the next quarter and is forecasted to reach -3.58 in one year’s time.
Technical Analysis of Nurix Therapeutics Inc (NRIX)
The latest stats from [Nurix Therapeutics Inc, NRIX] show that its last 5-days average volume of 1.25 million was superior to 0.88 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 49.35%.
During the past 100 days, Nurix Therapeutics Inc’s (NRIX) raw stochastic average was set at 11.55%, which indicates a significant decrease from 51.18% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.46 in the past 14 days, which was lower than the 0.60 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.94, while its 200-day Moving Average is $13.21. Now, the first resistance to watch is $9.22. This is followed by the second major resistance level at $9.51. The third major resistance level sits at $9.96. If the price goes on to break the first support level at $8.48, it is likely to go to the next support level at $8.04. Assuming the price breaks the second support level, the third support level stands at $7.75.
Nurix Therapeutics Inc (NASDAQ: NRIX) Key Stats
The company with the Market Capitalisation of 682.69 million has total of 76,449K Shares Outstanding. Its annual sales at the moment are 54,550 K in contrast with the sum of -193,570 K annual income. Company’s last quarter sales were recorded 44,060 K and last quarter income was -43,460 K.
